Ernexa Therapeutics (ERNA) Net Income towards Common Stockholders (2016 - 2025)
Historic Net Income towards Common Stockholders for Ernexa Therapeutics (ERNA) over the last 16 years, with Q3 2025 value amounting to -$1.2 million.
- Ernexa Therapeutics' Net Income towards Common Stockholders rose 9533.9% to -$1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$18.4 million, marking a year-over-year increase of 5916.26%. This contributed to the annual value of -$44.6 million for FY2024, which is 10547.41% down from last year.
- Latest data reveals that Ernexa Therapeutics reported Net Income towards Common Stockholders of -$1.2 million as of Q3 2025, which was up 9533.9% from -$3.1 million recorded in Q2 2025.
- Over the past 5 years, Ernexa Therapeutics' Net Income towards Common Stockholders peaked at -$1.2 million during Q3 2025, and registered a low of -$86.0 million during Q3 2021.
- Over the past 5 years, Ernexa Therapeutics' median Net Income towards Common Stockholders value was -$5.8 million (recorded in 2024), while the average stood at -$12.2 million.
- Per our database at Business Quant, Ernexa Therapeutics' Net Income towards Common Stockholders tumbled by 570594.19% in 2021 and then soared by 9533.9% in 2025.
- Quarter analysis of 5 years shows Ernexa Therapeutics' Net Income towards Common Stockholders stood at -$86.0 million in 2021, then surged by 94.77% to -$4.5 million in 2022, then tumbled by 37.0% to -$6.2 million in 2023, then rose by 6.4% to -$5.8 million in 2024, then skyrocketed by 78.5% to -$1.2 million in 2025.
- Its last three reported values are -$1.2 million in Q3 2025, -$3.1 million for Q2 2025, and -$8.2 million during Q1 2025.